COMP <GO>
ONC vs ABBV // FORWARD P/E MULTIPLE
BeOne Medicines Ltd. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ONC 5
— ABBV 10
▲ FORWARD P/E MULTIPLE LEADER: ABBV
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
forward-pe
123.6x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | 70.20% | +17.30 | ONC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 29.00% | -18.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 63.9x | 33.3x | +30.60 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.23% | 3.47% | -1.24 | ABBV | /fcf-yield <GO> |
| Operating Margin | 8.40% | 24.60% | -16.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 6.90% | -1.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 8.60% | +31.60 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 5.33 | +1.35 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | ONC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.7 | 72.8 | -20.10 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.15 | -0.17 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 123.6x | 113.1x | +10.50 | ABBV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $513.86B | -$471.61B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | ABBV REV | ONC GROSS % | ABBV GROSS % | ONC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $61.16B | 87.5% | 70.2% | $941.7M | $17.82B |
| FY 2024 | $3.81B | $56.33B | 84.4% | 70.0% | -$633.3M | $17.83B |
| FY 2023 | $2.46B | $54.32B | 44.0% | 44.0% | -$1.27B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
ABBV // BETA 1.15